Warner-Lambert is the proprietor of European Patent 0934061 which claims “Use of Pregablin for the preparation of a pharmaceutical composition for treating pain”. Pregablin is also used for the treatment of generalised anxiety disorder and epilepsy, although treatment...
Until now, exceptions to patent infringement in the UK were limited, so manufacturers preparing for regulatory approval risked an infringement action. Legislation will come into force in the UK on 1 October 2014 that finally provides broad exemption from patent...
Biopiracy is the evil sibling of bioprospecting. Bioprospecting is the search for existing genetic resources and biological knowledge that can be applied more widely and in novel applications. This is an area of particular interest to the pharmaceutical industry...
Finasteride was a known treatment for benign prostatic hyperplasia and Merck were granted a patent for this therapeutic application in 1978. Subsequently, Merck filed an application for the treatment of androgenic alopecia with a family of compounds including...
To be patentable a claim must be new and comprise an inventive step. Novelty is a question of fact: are all of the features of the claim present in a relevant single disclosure dating prior to the priority date of the patent application? However, the assessment of...
Concern and apprehension have been rife for patentees and practitioners alike in light of the Brüstle decision, which set out the CJEU’s decision as to what is and what is not excluded from patentability by the morality provisions of the Biotech Directive. Even...
![Omnipharm Limited v Merial [2011] EWHC 3393 (Pat)](https://www.schlich.co.uk/wp-content/uploads/2021/12/Omnipharm-Limited-v-Merial-2011-EWHC-3393-Pat.jpg)
Recent Comments